Sainsbury/ ASDA agreed a merger which will see US Walmart hold 42% of the enlarged group.
April 2018 saw a sharp rebound in UK blue chips which added c. 450 points due to M&A activity, higher commodity prices and declining UK gilt yields.
Glencore had a busy month with CEO Ivan Glasenberg resigning from Rusal following the US move to impose sanctions. Glencore was then sued for $2.95bn by Dan Gertler and freezing orders have been put in place on two of its DRC copper mines.
Takeda Pharmaceuticals fifth proposal to acquire Shire Pharmaceuticals got a tentative nod from the Shire board. The terms are 0.839x Takeda and $30.33 in cash per Shire share.
President Macron admitted that his visit to Washington to persuade US President Donald Trump to keep to the Iran nuclear deal “probably failed”.
Hammerson rejected a revised takeover proposal from Klepierre at 635p per share but facing increasing shareholder opposition then changed its mind on the merger with rival Intu Properties.
Barclays reported Q1 loss of £236m with TNAV declining to 251p from 276p. CEO Jes Staley promised to increase shareholder returns via a share buyback, but did not provide further details.
|1 May||Markit/ CIPS Manufacturing PMI/ BoE Consumer Credit|
|2 May||Construction PMI|
|3 May||Local Government Elections / 5 YR Treasury Auction|
|4 May||New Car Sales|
|8 May||Halifax House Price Index|
|10 May||UK Balance of Trade/ UK Industrial Production/ UK Manufacturing Production/ MPC meeting|
|15 May||UK Unemployment Rate/ Average Earnings/ Claimant Count Change|
|16 May||Labour Productivity QTR|
|21 May||CBI Industrial Trends|
|22 May||Public Sector Net Borrowing|
|23 May||PPI Output/ Retail Price Index/ Inflation Rate|
|DOW JONES (Close)||24,163.15||60.15||0.25||15.53|
|S&P 500 (Close)||2,648.05||7.18||0.27||10.87|
|UK 100 INDEX (Close)||7,509.30||452.69||6.41||3.57|
|CAC 40 INDEX (Close)||5,520.50||353.20||6.83||4.07|
|EUROSTOXX 50 (Close)||3,534.19||172.69||5.13||-1.23|
|SHANGHAI COMPOSITE (Close)||3,082.23||-86.67||-2.81||-1.95|
|ASX 200 (Close)||5,982.70||229.10||3.82||0.54|
|HANG SENG (Close)||30,808.45||785.92||2.61||24.75|
UK blue chips bounced 452 points during April on the back of higher commodities, lower sterling and expectations that the Bank of England is dialing back on its rate rise agenda. Speaking at the IMF meeting in Washington Governor Mark Carney suggested that the MPC could wait longer.
Saudi Arabia’s apparent intention to keep crude oil above $70/ barrel, the prospect of new sanctions on Iran which could remove 800k barrels of Iranian crude from the global market and strong global GDP growth have kept Brent underpinned, boosting UK oil majors and oil services.
M&A is a major feature in 2018 with deals being rushed through whilst sterling remains cheap. But not all M&A gets to the finish line, if anything it has become harder to complete. And it is taking longer these days to get completion.
|Target||Acquirer||No of attempts||Comment|
|Smurfitt Kappa||Intl Paper||3||Smurfitt are wanting an unrealistic price|
|Shire Ph.||Takeda||5||Shire wants alternative buyer|
|Sky||Comcast||2||Ball is now in Fox / Disney court|
Tokyo investors are concerned about Takeda Pharmaceuticals whose new CEO, Frenchman Christophe Weber is hell bent on acquiring Shire Pharmaceuticals following on from recent bolt on acquisitions. The Shire merger, if completed, will see Takeda shouldering a debt of c. US$40bn has caused a significant sell off in Takeda’s shares.
Takeda is taking significant risks, especially if the Trump Administration pursues pharmaceutical price cuts, which would hit the pricing of Shire’s expensive rare drugs.
The proposed merger has left many analysts scratching their heads as to its merits, as there do not appear to be significant synergies or overlap. Weber still has to get his shareholders onboard, and arrange financing. The whole process has shown Takeda is desperate to buy Shire.
French tycoon, Vincent Bollore has hit back against allegations that he undercharged the presidents of Guinea and Togo for advertising on their election campaigns as an incentive to award Bollore Group port concessions. Bollore claimed that the claims were rooted in prejudice against African leaders.
Bollore SA shares dropped from highs of €4.50 on April 19th 2018 to €4.12 on concern that the corruption probe might uncover wrongdoing in its lucrative port and oil storage operations in west Africa. There may also be executive changes. The Euro declined noticeably vs. the USD over April reversing from highs of $1.24 to just above $1.20.
The US Q1 season started with high expectations, consensus for the S&P 500 was a 24.6% rise in earnings, according to Reuters. Excluding the energy sector the Q1 earnings growth estimate was around 22.8%. These were very high forecasts.
Of the 274 / 500 US companies that have so far reported, 79.2% have reported earnings above estimates (above the long term average of 64%) whilst average revenue growth has been 8.1%.
Q1 earnings growth has been helped by cuts in corporation tax but this is part of the 2018 story. Robust global growth is also important.
The US market is skewed with the top ten technology companies expected to reach $1trn in revenues in 2018. Recent moves in the “market cap wars” has seen movie streaming giant Netflix (NASDAQ: NFLX) market cap reach $136.5bn just above IBM (NYSE: IBM) at $133.75bn. Facebook market cap at $500bn exceeds both Exxon Mobil ($342bn) and Walt Disney ($152bn). Sign of the times?
Philip Morris fell after Q1 tobacco shipments declined 5.3% meaning revenues were $103m behind forecasts of $7.03bn. Smokers have proved slow to move to “next generation” vaping and heated tobacco products.
Buy: A “buy” rating is applied to companies with established businesses that are profitable and where there is further profit growth expected. A “buy” recommendation means the analyst expects the share to reach the share price target on the note.
Hold: The company’s valuation appears to reflect investor expectations in the short-term. Alternatively the company is awaiting key developments that will impact on the share price. Investors are advised to await the resolution of these key developments.
Sell: The company’s valuation appears too high having regard to material uncertainties, declining profit prospects or has sizeable funding requirements. A sell recommendation may also be applied where the board have failed in key objectives or appear to be frequently changing strategy. A sell recommendation means the analyst expects the share to fall to the price target on the note.
Neutral (Not Rated): The analyst does not maintain a view in either direction.
Please be aware that the following disclosures of Material Interests are relevant to this technical note:
Shire Pharma Relevant disclosures: <2>
Hammerson Relevant disclosures: <2>
Takeda Pharma Relevant disclosures: <2>
Bollore SA Relevant disclosures: <2>
J Sainsbury Relevant disclosures: <2>
Glencore Relevant disclosures: <2>
IBM Relevant disclosures: <2>
Walt Disney Relevant disclosures: <2>
Facebook Relevant disclosures: <2>
Philip Morris Int Relevant disclosures: <NA>
Smurfitt Kappa Relevant disclosures: <2>
Comcast Relevant disclosures: <NA>
Sky Relevant disclosures: <2>
Barclays Relevant disclosures: <2>
The report’s author certifies that this research report accurately states his personal views about the subject security, which is reflected in the ratings as well as the substance of the report.
Collins Sarri Statham Investments Ltd (CSS) does not in any of its publications take into account any particular recipient's investment objectives, financial situation, and specific needs and demands. Therefore, all CSS publications are, unless otherwise specifically stated, intended for informational and/or marketing purposes only. CSS shall not be responsible for any loss arising from any investment based on a perceived recommendation.
No publication (including recommendations) shall be construed as a representation or warranty that the recipient will profit, nor avoid sustaining losses, from trading in accordance with a trading strategy set forth in a publication.
This research is non-independent and is classified as a Marketing Communication under FCA rules detailed in their Conduct of Business Rulebook (COBS). As such it has not been prepared in accordance with legal requirements designed to promote independence of investment research and it is not subject to the prohibition of dealing ahead of the dissemination of investment research outlined in COBS 12.2.5.
Trading in the products and services offered by Collins Sarri Statham Investments Ltd (CSS) may, result in losses as well as profits as the value of investments may go down as well as up. You may not get back the full amount you have invested. Any reference to past performance should not be viewed as an indication of any future performance. Investments held in overseas markets are subject to the effects of changes in exchange rates which will impact on the value of the underlying investment. Investments made in AIM and penny shares carry an increased risk due to the difficulty in creating a market in these shares. There may be a substantial difference in the buy and sell price. Leveraged products such as Contracts for Difference (CFDs), derivatives, commodities & Foreign Exchange (FX), carry a higher risk to your capital. They can lose their value rapidly and you may lose substantially more than your initial investment. A higher risk to your capital. They can lose their value rapidly and you may lose substantially more than your initial investment.
The information contained herein is based on materials and sources that we believe to be reliable however we make no representation or warranty, either express or implied, in relation to the accuracy, completeness or reliability of the information contained herein. Please note that the figures shown may, in some instances, be rounded to the nearest penny. Prices can move sharply from those quoted in this document. Current prices can be verified by calling one of our brokers. CSS is under no obligation to update the information contained herein. Neither CSS, nor its affiliates, nor its employees shall have any liability whatsoever for any indirect or consequential loss or damage arising from the use of this document.